Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) is an uncommon T-cell non-Hodgkin Lymphoma (NHL) associated with breast implants. Raising awareness of the possibility of BIA-ALCL in anyone with breast implants and new breast symptoms is crucial to early diagnosis. The tumour begins on the inner aspect of the peri-implant capsule causing an effusion, or less commonly a tissue mass to form within the capsule, which may spread locally or to more distant sites in the body. Diagnosis is usually made by cytological, immunohistochemical and immunophenotypic evaluation of the aspirated peri-implant fluid: pleomorphic lymphocytes are characteristically anaplastic lymphoma kinase (ALK)-negative and strongly positive for CD30. BIA-ALCL is indolent in most patients but can progress rapidly. Surgical removal of the implant with the intact surrounding capsule (total en-bloc capsulectomy) is usually curative. Late diagnosis may require more radical surgery and systemic therapies and although these are usually successful, poor outcomes and deaths have been reported. By adopting a structured approach, as suggested in these guidelines, early diagnosis and successful treatment will minimise the need for systemic treatments, reduce morbidity and the risk of poor outcomes.

Barts Health NHS Trust London UK

Bristol Plastic Surgery Bristol UK

CEITEC Masaryk University Brno Czech Republic

Cobalt Medical Charity Cheltenham UK

Division of Cellular and Molecular Pathology Department of Pathology University of Cambridge Cambridge UK

Gloucestershire Hospitals NHS Foundation Trust Gloucester UK

Royal Free Hospital London UK

Royal Marsden NHS Foundation Trust London UK

St James's Hospital The Leeds Teaching Hospitals NHS Trust Leeds UK

Zobrazit více v PubMed

Cronin TD, Greenberg RL. Our experiences with the silastic gel breast prosthesis. Plast Reconstr Surg. 1970;46(1):1–7. PubMed

Food and Drug Administration . FDA update on the safety of silicone gel‐filled breast implants 2011 [cited 2020 April]. Available from: https://www.fda.gov/media/80685/download

de Boer M, van Leeuwen FE, Hauptmann M, Overbeek LIH, de Boer JP, Hijmering NJ, et al. Breast implants and the risk of anaplastic large‐cell lymphoma in the breast. JAMA Oncol. 2018;4(3):335–41. PubMed PMC

Food and Drug Administration . Oral contribution from the European Taskforce on Breast Implant Associated‐ALCL for FDA Hearing on Breast Implants 2019. Available from: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/793015/TF_Oral_Comunication_FDA_Hearing_POST_TC_21_March.pdf

Independent Review Group . Silicone Gel Breast Implants: The Report of the Independent Review Group Cambridge. England: Jill Rogers Associates; 1998. Available from: https://webarchive.nationalarchives.gov.uk/20110504132647/http://www.mhra.gov.uk/Safetyinformation/Generalsafetyinformationandadvice/Product‐specificinformationandadvice/Product‐specificinformationandadvice‐A‐F/Breastimplants/Siliconegelbreastimplants/IndependentReviewGroup‐siliconegelbreastimplants/index.htm

Bondurant S. Safety of Silicone Breast Implants In: Bondurant S, Ernster V, Herdman R, editors. Safety of silicone breast implants. Washington, DC: National Academies Press, 1999. PubMed

Keech JA Jr. Anaplastic T‐cell lymphoma in proximity to a saline‐filled breast implant. Plast Reconstr Surg. 1997;100(2):554–5. PubMed

Newman MK, Zemmel NJ, Bandak AZ, Kaplan BJ. Primary breast lymphoma in a patient with silicone breast implants: a case report and review of the literature. J Plast Reconstr Aesthet Surg. 2008;61(7):822–5. PubMed

Thomas A, Link BK, Altekruse S, Romitti PA, Schroeder MC. Primary Breast Lymphoma in the United States: 1975‐2013. J Natl Cancer Inst. 2017;109(6):1–8. PubMed PMC

Howlader NNA, Krapcho M, Miller D, Brest A, Yu M, Ruhl J, et al.SEER Cancer Statistics Review, 1975‐2016, National Cancer Institute. Bethesda, MD, 2019. Available from: https://seer.cancer.gov/csr/1975_2016/

Feuer EJ, Wun LM, Boring CC, Flanders WD, Timmel MJ, Tong T. The lifetime risk of developing breast cancer. J Natl Cancer Inst. 1993;85(11):892–7. PubMed

U.S. Food and Drug Administration . Anaplastic Large Cell Lymphoma (ALCL) in women with breast implants: Preliminary FDA Findings and Analyses; 2011. Available from: http://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/ImplantsandProsthetics/BreastImplants/ucm239996.htm

Medicines and Healthcare products Regulatory Agency . Breast implants and Anaplastic Large Cell Lymphoma (ALCL). Information for clinicians and patients. 2017. [updated May 2020]. Available from: https://www.gov.uk/guidance/breast‐implants‐and‐anaplastic‐large‐cell‐lymphoma‐alcl#history

Brody G, Deapen D, Taylor C, Pinter‐Brown L, House‐Lightner SR, Andersen J, et al. Anaplastic large cell lymphoma occurring in women with breast implants: analysis of 173 cases. Plast Reconstr Surg. 2015;135(3):695–705. PubMed

Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375–90. PubMed PMC

Food and Drug Administration . Medical Device Reports of Breast Implant‐Associated Anaplastic Large Cell Lymphoma 2019. Available from: https://www.fda.gov/medical‐devices/breast‐implants/medical‐device‐reports‐breast‐implant‐associated‐anaplastic‐large‐cell‐lymphoma PubMed

Johnson L, O'Donoghue JM, McLean N, Turton P, Khan AA, Turner SD, et al. Breast implant associated anaplastic large cell lymphoma: the UK experience. Recommendations on its management and implications for informed consent. Eur J Surg Oncol. 2017;43(8):1393–401. PubMed

Doren EL, Miranda RN, Selber JC, Garvey PB, Liu J, Medeiros LJ, et al. U.S. Epidemiology of breast implant‐associated anaplastic large cell lymphoma. Plast Reconstr Surg. 2017;139(5):1042–50. PubMed

Leberfinger AN, Behar BJ, Williams NC, Rakszawski KL, Potochny JD, Mackay DR, et al. Breast implant‐associated anaplastic large cell lymphoma: a systematic review. JAMA Surg. 2017;152(12):1161–8. PubMed

Loch‐Wilkinson A, Beath KJ, Knight RJW, Wessels WLF, Magnusson M, Papadopoulos T, et al. Breast implant‐associated anaplastic large cell lymphoma in Australia and New Zealand: high‐surface‐area textured implants are associated with increased risk. Plast Reconstr Surg. 2017;140(4):645–54. PubMed

Srinivasa DR, Miranda RN, Kaura A, Francis AM, Campanale A, Boldrini R, et al. Global adverse event reports of breast implant‐associated ALCL: an International Review of 40 Government Authority Databases. Plast Reconstr Surg. 2017;139(5):1029–39. PubMed

Ghione P, Cordeiro PG, Ni A, Hu Q, Ganesan N, Galasso N, et al. Risk of breast implant‐associated anaplastic large cell lymphoma (BIA‐ALCL) in a cohort of 3,546 women prospectively followed after receiving textured breast implants. J. Clin. Oncol.. 2019;37(15_suppl):1565.

Cordeiro PG, Ghione P, Ni A, Hu Q, Ganesan N, Galasso N, et al. Risk of breast implant associated anaplastic large cell lymphoma (BIA‐ALCL) in a cohort of 3546 women prospectively followed long term after reconstruction with textured breast implants. J Plast Reconstr Aesthet Surg. 2020;73(5):841–6. PubMed PMC

Loch‐Wilkinson A, Beath KJ, Magnusson MR, Cooter R, Shaw K, French J, et al. Breast implant‐associated anaplastic large cell lymphoma in Australia: a longitudinal study of implant and other related risk factors. Aesthet Surg J. 2019;40(8):838–46. PubMed

Mercer NSG. Editorial on the article "Risk of breast implant associated anaplastic large cell lymphoma in a cohort of 3546 women prospectively followed long term after reconstruction with macro‐textured breast implants. J Plast Reconstr Aesthet Surg. 2020;73(5):847–9. PubMed

National Comprehensive Cancer Network . NCCN Guidelines For Treatment of Cancer by Site 2016 [updated 2019]. Available from: https://www.nccn.org/professionals/physician_gls/default.aspx#site

Clemens MW, Horwitz SM. NCCN Consensus Guidelines for the Diagnosis and Management of Breast Implant‐Associated Anaplastic Large Cell Lymphoma. Aesthet Surg J. 2017;37(3):285–9. PubMed

Clemens MW, Jacobsen ED, Horwitz SM. NCCN Consensus Guidelines on the Diagnosis and Treatment of Breast Implant‐Associated Anaplastic Large Cell Lymphoma (BIA‐ALCL). Aesthetic Surg J. 2019;39(Suppl_1):S3–S13. PubMed

Jones JL, Hanby AM, Wells C, Calaminici M, Johnson L, Turton P, et al. Breast implant‐associated anaplastic large cell lymphoma (BIA‐ALCL): an overview of presentation and pathogenesis and guidelines for pathological diagnosis and management. Histopathology. 2019;75(6):787–96. PubMed

Clinical Audit and Registries Management Service NHS Digital . Breast and Cosmetic Implant Registry: England July 2018 ‐ July 2019, managment information; 2019. Available from: https://files.digital.nhs.uk/62/8C3560/BCIR_Report_2019.pdf

Lowes S, MacNeill F, Martin L, O'Donoghue JM, Pennick MO, Redman A, et al. Breast imaging for aesthetic surgery: British Society of Breast Radiology (BSBR), Association of Breast Surgery Great Britain & Ireland (ABS), British Association of Plastic Reconstructive and Aesthetic Surgeons (BAPRAS). J Plast Reconstr Aesthet Surg. 2018;71(11):1521–31. PubMed

Miranda RN, Aladily TN, Prince HM, Kanagal‐Shamanna R, de Jong D, Fayad LE, et al. Breast implant‐associated anaplastic large‐cell lymphoma: long‐term follow‐up of 60 patients. J Clin Oncol. 2014;32(2):114–20. PubMed PMC

McCarthy CM, Loyo‐Berrios N, Qureshi AA, Mullen E, Gordillo G, Pusic AL, et al. Patient Registry and Outcomes for Breast Implants and Anaplastic Large Cell Lymphoma Etiology and Epidemiology (PROFILE): Initial Report of Findings, 2012‐2018. Plast Reconstr Surg. 2019;143(3S A Review of Breast Implant‐Associated Anaplastic Large Cell Lymphoma):65S–73S. PubMed PMC

Clemens MW, Medeiros LJ, Butler CE, Hunt KK, Fanale MA, Horwitz S, et al. Complete surgical excision is essential for the management of patients with breast implant‐associated anaplastic large‐cell lymphoma. J Clin Oncol. 2016;34(2):160–8. PubMed PMC

Adrada BE, Miranda RN, Rauch GM, Arribas E, Kanagal‐Shamanna R, Clemens MW, et al. Breast implant‐associated anaplastic large cell lymphoma: Sensitivity, specificity, and findings of imaging studies in 44 patients. Breast Cancer Res Treat. 2014;147(1):1–14. PubMed

McGuire P, Reisman NR, Murphy DK. Risk Factor Analysis for Capsular Contracture, Malposition, and Late Seroma in Subjects Receiving Natrelle 410 Form‐Stable Silicone Breast Implants. Plast Reconstr Surg. 2017;139(1):1–9. PubMed PMC

Pinchuk V, Tymofii O. Seroma as a late complication after breast augmentation. Aesthetic Plast Surg. 2011;35(3):303–14. PubMed

National Institute for Health and Care Excellence . Familial breast cancer: classification, care and managing breast cancer and related risks in people with a family history of breast cancer 2013. Available from: https://www.nice.org.uk/guidance/cg164 PubMed

Adlard J, Burton C, Turton P. Increasing evidence for the association of breast implant‐associated anaplastic large cell lymphoma and Li Fraumeni Syndrome. Case Rep Genet. 2019;2019:5647940. PubMed PMC

De Boer M, Hauptmann M, Hijmering NJ, van Noesel CJM, Rakhorst HA, Meijers‐Heijboer HE, et al. Increased prevalence of BRCA1/2 mutations in women with macro‐textured breast implants and anaplastic large cell lymphoma of the breast. Blood. 2020;136(11):1368–72. PubMed

National Genomic Test Directory Testing Criteria for Rare and Inherited Disease: NHS England; Available from: https://www.england.nhs.uk/wp‐content/uploads/2018/08/rare‐and‐inherited‐disease‐eligibility‐criteria‐march‐19.pdf

Bengtson B, Brody G, Brown M, Glicksman C, Hammond D, Kaplan H, et al. Managing late periprosthetic fluid collections (Seroma) in patients with breast implants: a consensus panel recommendation and review of the literature. Plast Reconstr Surg. 2011;128(1):1–7. PubMed

Seiler SJ, Sharma PB, Hayes JC, Ganti R, Mootz AR, Eads ED, et al. Multimodality imaging‐based evaluation of single‐lumen silicone breast implants for rupture. Radiographics. 2017;37(2):366–82. PubMed

Sharma B, Jurgensen‐Rauch A, Pace E, Attygalle AD, Sharma R, Bommier C, et al. Breast implant‐associated anaplastic large cell lymphoma: review and multiparametric imaging paradigms. Radiographics. 2020;40(3):609–28. PubMed

Montes Fernandez M, Ciudad Fernandez MJ, de la Puente YM, Brenes Sanchez J, Benito Arjonilla E, Moreno Dominguez L, et al. Breast implant‐associated Anaplastic large cell lymphoma (BIA‐ALCL): Imaging findings. Breast J. 2019;25(4):728–30. PubMed

Barrington SF, Mikhaeel NG, Kostakoglu L, Meignan M, Hutchings M, Mueller SP, et al. Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group. J Clin Oncol. 2014;32(27):3048–58. PubMed PMC

Di Napoli A, Pepe G, Giarnieri E, Cippitelli C, Bonifacino A, Mattei M, et al. Cytological diagnostic features of late breast implant seromas: from reactive to anaplastic large cell lymphoma. PLoS One. 2017;12(7):e0181097. PubMed PMC

National Institute for Health and Care Excellence . Haematological cancers: improving outcomes NICE guideline [NG47] 2016. Available from: https://www.nice.org.uk/guidance/ng47 PubMed

Rodriguez‐Pinilla SM, Sanchez‐Garcia FJ, Balague O, Rodriguez‐Justo M, Piris MA. Breast implant‐associated EBV‐positive large B‐cell lymphomas: report of three cases. Haematologica. 2019;105(8):e412–4. PubMed PMC

Kadin ME. Regulation of CD30 antigen expression and its potential significance for human disease. Am J Pathol. 2000;156(5):1479–84. PubMed PMC

Jaffe ES, Ashar BS, Clemens MW, Feldman AL, Gaulard P, Miranda RN, et al. Best practices guideline for the pathologic diagnosis of breast implant‐associated anaplastic large‐cell lymphoma. J Clin Oncol. 2020;38(10):1102–11. PubMed PMC

Laurent C, Delas A, Gaulard P, Haioun C, Moreau A, Xerri L, et al. Breast implant‐associated anaplastic large cell lymphoma: two distinct clinicopathological variants with different outcomes. Ann Oncol. 2016;27(2):306–14. PubMed PMC

Blombery P, Thompson E, Ryland GL, Joyce R, Byrne DJ, Khoo C, et al. Frequent activating STAT3 mutations and novel recurrent genomic abnormalities detected in breast implant‐associated anaplastic large cell lymphoma. Oncotarget. 2018;9(90):36126–36. PubMed PMC

Laurent C, Nicolae A, Laurent C, Le Bras F, Haioun C, Fataccioli V, et al. Gene alterations in epigenetic modifiers and JAK‐STAT signaling are frequent in breast implant‐associated ALCL. Blood. 2020;135(5):360–70. PubMed PMC

Oishi N, Brody GS, Ketterling RP, Viswanatha DS, He R, Dasari S, et al. Genetic subtyping of breast implant‐associated anaplastic large cell lymphoma. Blood. 2018;132(5):544–7. PubMed PMC

Letourneau A, Maerevoet M, Milowich D, Dewind R, Bisig B, Missiaglia E, et al. Dual JAK1 and STAT3 mutations in a breast implant‐associated anaplastic large cell lymphoma. Virchows Arch. 2018;473(4):505–11. PubMed

Di Napoli A, Jain P, Duranti E, Margolskee E, Arancio W, Facchetti F, et al. Targeted next generation sequencing of breast implant‐associated anaplastic large cell lymphoma reveals mutations in JAK/STAT signalling pathway genes, TP53 and DNMT3A. Br J Haematol. 2018;180(5):741–4. PubMed

Turner SD, Inghirami G, Miranda RN, Kadin ME. Cell of Origin and Immunologic events in the pathogenesis of breast implant‐associated anaplastic large‐cell lymphoma. Am J Pathol. 2020;190(1):2–10. PubMed PMC

Turner SD. The Cellular Origins of Breast Implant‐Associated Anaplastic Large Cell Lymphoma (BIA‐ALCL): implications for immunogenesis. Aesthet Surg J. 2019;39(Suppl_1):S21‐S7. PubMed PMC

Blombery P, Thompson ER, Jones K, Arnau GM, Lade S, Markham JF, et al. Whole exome sequencing reveals activating JAK1 and STAT3 mutations in breast implant‐associated anaplastic large cell lymphoma anaplastic large cell lymphoma. Haematologica. 2016;101(9):e387–e390. PubMed PMC

Pastorello RG, D'Almeida Costa F, Osorio C, Makdissi FBA, Bezerra SM, de Brot M, et al. Breast implant‐associated anaplastic large cell lymphoma in a Li‐FRAUMENI patient: a case report. Diagn Pathol. 2018;13(1):10. PubMed PMC

Malcolm TI, Hodson DJ, Macintyre EA, Turner SD. Challenging perspectives on the cellular origins of lymphoma. Open Biol. 2016;6(9). PubMed PMC

Kadin ME, Morgan J, Xu H, Epstein AL, Sieber D, Hubbard BA, et al. IL‐13 is produced by tumor cells in breast implant‐associated anaplastic large cell lymphoma: implications for pathogenesis. Hum Pathol. 2018;78:54–62. PubMed

Kadin ME. Commentary on: a case report of a breast implant‐associated plasmacytoma and literature review of non‐ALCL breast implant‐associated neoplasms. Aesthet Surg J. 2019;39(7):NP240‐NP2. PubMed

Zambacos GJ, Molnar C, Mandrekas AD. Silicone lymphadenopathy after breast augmentation: case reports, review of the literature, and current thoughts. Aesthetic Plast Surg. 2013;37(2):278–89. PubMed

Lee Y, Song SE, Yoon ES, Bae JW, Jung SP. Extensive silicone lymphadenopathy after breast implant insertion mimicking malignant lymphadenopathy. Ann Surg Treat Res. 2017;93(6):331–5. PubMed PMC

Katzin WE, Centeno JA, Feng LJ, Kiley M, Mullick FG. Pathology of lymph nodes from patients with breast implants: a histologic and spectroscopic evaluation. Am J Surg Pathol. 2005;29(4):506–11. PubMed

Lamaris GA, Butler CE, Deva AK, Miranda RN, Hunt KK, Connell T, et al. Breast Reconstruction Following Breast Implant‐Associated Anaplastic Large Cell Lymphoma. Plast Reconstr Surg. 2019;143(3S A Review of Breast Implant‐Associated Anaplastic Large Cell Lymphoma):51S‐8S. PubMed

Talagas M, Uguen A, Charles‐Petillon F, Conan‐Charlet V, Marion V, Hu W, et al. Breast implant‐associated anaplastic large‐cell lymphoma can be a diagnostic challenge for pathologists. Acta Cytol. 2014;58(1):103–7. PubMed

Lyapichev KA, Pina‐Oviedo S, Medeiros LJ, Evans MG, Liu H, Miranda AR, et al. A proposal for pathologic processing of breast implant capsules in patients with suspected breast implant anaplastic large cell lymphoma. Mod Pathol. 2019;33(3):367–79. PubMed PMC

Dearden CE, Johnson R, Pettengell R, Devereux S, Cwynarski K, Whittaker S, et al. Guidelines for the management of mature T‐cell and NK‐cell neoplasms (excluding cutaneous T‐cell lymphoma). Br J Haematol. 2011;153(4):451–85. PubMed

Abouyabis AN, Shenoy PJ, Sinha R, Flowers CR, Lechowicz MJ. A systematic review and meta‐analysis of front‐line anthracycline‐based chemotherapy regimens for peripheral T‐cell lymphoma. Isrn Hematol. 2011;2011:623924. PubMed PMC

Schmitz N, Trumper L, Ziepert M, Nickelsen M, Ho AD, Metzner B, et al. Treatment and prognosis of mature T‐cell and NK‐cell lymphoma: an analysis of patients with T‐cell lymphoma treated in studies of the German High‐Grade Non‐Hodgkin Lymphoma Study Group. Blood. 2010;116(18):3418–25. PubMed

d'Amore F, Relander T, Lauritzsen GF, Jantunen E, Hagberg H, Anderson H, et al. Up‐front autologous stem‐cell transplantation in peripheral T‐cell lymphoma: NLG‐T‐01. J Clin Oncol. 2012;30(25):3093–9. PubMed

d'Amore F, Gaulard P, Trumper L, Corradini P, Kim WS, Specht L, et al. Peripheral T‐cell lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow‐up. Ann Oncol. 2015;26(Suppl 5):v108–v115. PubMed

Kim YA, Byun JM, Park K, Bae GH, Lee D, Kim DS, et al. Redefining the role of etoposide in first‐line treatment of peripheral T‐cell lymphoma. Blood Adv. 2017;1(24):2138–46. PubMed PMC

Deng S, Lin S, Shen J, Zeng Y. Comparison of CHOP vs CHOPE for treatment of peripheral T‐cell lymphoma: a meta‐analysis. Onco Targets Ther. 2019;12:2335–42. PubMed PMC

Horwitz S, O'Connor OA, Pro B, Illidge T, Fanale M, Advani R, et al. Brentuximab vedotin with chemotherapy for CD30‐positive peripheral T‐cell lymphoma (ECHELON‐2): a global, double‐blind, randomised, phase 3 trial. Lancet. 2019;393(10168):229–40. PubMed PMC

Pro B, Advani R, Brice P, Bartlett NL, Rosenblatt JD, Illidge T, et al. Brentuximab vedotin (SGN‐35) in patients with relapsed or refractory systemic anaplastic large‐cell lymphoma: results of a phase II study. J Clin Oncol. 2012;30(18):2190–6. PubMed

Bartlett NL, Chen R, Fanale MA, Brice P, Gopal A, Smith SE, et al. Retreatment with brentuximab vedotin in patients with CD30‐positive hematologic malignancies. J Hematol Oncol. 2014;7:24. PubMed PMC

Stack A, Levy I. Brentuximab vedotin as monotherapy for unresectable breast implant‐associated anaplastic large cell lymphoma. Clin Case Rep. 2019;7(5):1003–6. PubMed PMC

Alderuccio JP, Desai A, Yepes MM, Chapman JR, Vega F, Lossos IS. Frontline brentuximab vedotin in breast implant‐associated anaplastic large‐cell lymphoma. Clin Case Rep. 2018;6(4):634–7. PubMed PMC

El‐Asmar J, Reljic T, Ayala E, Hamadani M, Nishihori T, Kumar A, et al. Efficacy of High‐Dose Therapy and Autologous Hematopoietic Cell Transplantation in Peripheral T Cell Lymphomas as Front‐Line Consolidation or in the Relapsed/Refractory Setting: A Systematic Review/Meta‐Analysis. Biol Blood Marrow Transplant. 2016;22(5):802–14. PubMed

Fossard G, Broussais F, Coelho I, Bailly S, Nicolas‐Virelizier E, Toussaint E, et al. Role of up‐front autologous stem‐cell transplantation in peripheral T‐cell lymphoma for patients in response after induction: an analysis of patients from LYSA centers. Ann Oncol. 2018;29(3):715–23. PubMed

Park SI, Horwitz SM, Foss FM, Pinter‐Brown LC, Carson KR, Rosen ST, et al. The role of autologous stem cell transplantation in patients with nodal peripheral T‐cell lymphomas in first complete remission: report from COMPLETE, a prospective, multicenter cohort study. Cancer. 2019;125(9):1507–17. PubMed PMC

Tang T, Chen Z, Praditsuktavorn P, Khoo LP, Ruan J, Lim ST, et al. Role of surveillance imaging in patients with peripheral T‐cell lymphoma. Clin Lymphoma Myeloma Leuk. 2016;16(3):117–21. PubMed

Cederleuf H, Hjort Jakobsen L, Ellin F, de Nully BP, Stauffer Larsen T, Bogsted M, et al. Outcome of peripheral T‐cell lymphoma in first complete remission: a Danish‐Swedish population‐based study. Leuk Lymphoma. 2017;58(12):2815–23. PubMed

Armitage JO. Who benefits from surveillance imaging? J Clin Oncol. 2012;30(21):2579–80. PubMed

Dann EJ, Berkahn L, Mashiach T, Frumer M, Agur A, McDiarmid B, et al. Hodgkin lymphoma patients in first remission: routine positron emission tomography/computerized tomography imaging is not superior to clinical follow‐up for patients with no residual mass. Br J Haematol. 2014;164(5):694–700. PubMed

Thompson CA, Ghesquieres H, Maurer MJ, Cerhan JR, Biron P, Ansell SM, et al. Utility of routine post‐therapy surveillance imaging in diffuse large B‐cell lymphoma. J Clin Oncol. 2014;32(31):3506–12. PubMed PMC

Hicks LK, Bering H, Carson KR, Kleinerman J, Kukreti V, Ma A, et al. The ASH Choosing Wisely(R)campaign: five hematologic tests and treatments to question. Hematology Am Soc Hematol Educ Program. 2013;2013:9–14. PubMed